VELCADE (bortezomib)
ANTINEOPLASTIC - PROTEASOME ENZYME INHIBITORS·MULTIPLE MYELOMA·+1
MILLENNIUM PHAR
Indication
Mantle cell lymphoma
Mantle cell lymphoma is a rare, typically aggressive subtype of B-cell non-Hodgkin lymphoma arising from mature pregerminal center B lymphocytes in the mantle zone of lymph nodes. Read more about Mantle cell lymphoma
49 drugs 40 manufacturers
Drugs that treat it
Common Mantle cell lymphoma therapies.
REVLIMID (lenalidomide)
MULTIPLE MYELOMA·+6
CELGENE
BORTEZOMIB
ANTINEOPLASTIC - PROTEASOME ENZYME INHIBITORS·MULTIPLE MYELOMA·+1
FRESENIUS KABI
CALQUENCE (acalabrutinib)
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·CHRONIC LYMPHOCYTIC LEUKEMIA·+2
AstraZeneca Pharmaceuticals
BORTEZOMIB
ANTINEOPLASTIC - PROTEASOME ENZYME INHIBITORS·MULTIPLE MYELOMA·+1
DR.REDDY'S LAB
BRUKINSA (zanubrutinib)
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·CHRONIC LYMPHOCYTIC LEUKEMIA·+5
BEONE MEDICINES
TECARTUS (brexucabtagene autoleucel)
ANTINEOPLASTIC - CAR-T/TCR-T CELL IMMUNOTHERAPY·MANTLE CELL LYMPHOMA·+1
KITE PHARMA, IN
BREYANZI (lisocabtagene maraleucel)
CHRONIC LYMPHOCYTIC LEUKEMIA·+6
JUNO THERAPEUTI
REVLIMID (lenalidomide)
THALIDOMIDE AND DERIVATIVE IMMUNOMODULATORS·MULTIPLE MYELOMA·+6
CELGENE/BMS
Filter & compare in the drug finder →Opens the drug finder with Mantle cell lymphoma preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonMantle cell lymphoma is a rare, typically aggressive subtype of B-cell non-Hodgkin lymphoma arising from mature pregerminal center B lymphocytes in the mantle zone of lymph nodes.
It primarily affects older adults, with a marked male predominance, and predominantly involves the lymphatic and hematopoietic systems, frequently presenting with generalized lymphadenopathy alongside extranodal dissemination to the bone marrow, peripheral blood, spleen, and gastrointestinal tract.
Pathophysiologically, the hallmark feature is the chromosomal translocation t(11;14)(q13;q32), which juxtaposes the *CCND1* gene with the immunoglobulin heavy chain locus, driving constitutive cyclin D1 overexpression and uncontrolled cell cycle progression.
- nih.gov
Mantle cell lymphoma is a rare, typically aggressive subtype of B-cell non-Hodgkin lymphoma arising from mature pregerminal center B lymphocytes in the mantle zone of lymph nodes It primarily affects older adults, with a marked male predominance, and predominantly involves the lymphatic and hematopoietic systems, frequently presenting with generalized lymphadenopathy alongside extranodal dissemination to the bone marrow, peripheral blood, spleen, and gastrointestinal tract Pathophysiologically, ...
- nih.gov
Mantle cell lymphoma is a rare, typically aggressive subtype of B-cell non-Hodgkin lymphoma arising from mature pregerminal center B lymphocytes in the mantle zone of lymph nodes It primarily affects older adults, with a marked male predominance, and predominantly involves the lymphatic and hematopoietic systems, frequently presenting with generalized lymphadenopathy alongside extranodal dissemination to the bone marrow, peripheral blood, spleen, and gastrointestinal tract Pathophysiologically, ...
- mdanderson.org
Mantle cell lymphoma is a rare, typically aggressive subtype of B-cell non-Hodgkin lymphoma arising from mature pregerminal center B lymphocytes in the mantle zone of lymph nodes It primarily affects older adults, with a marked male predominance, and predominantly involves the lymphatic and hematopoietic systems, frequently presenting with generalized lymphadenopathy alongside extranodal dissemination to the bone marrow, peripheral blood, spleen, and gastrointestinal tract
- cancer.gov
It primarily affects older adults, with a marked male predominance, and predominantly involves the lymphatic and hematopoietic systems, frequently presenting with generalized lymphadenopathy alongside extranodal dissemination to the bone marrow, peripheral blood, spleen, and gastrointestinal tract
- nih.gov
Pathophysiologically, the hallmark feature is the chromosomal translocation t(11;14)(q13;q32), which juxtaposes the *CCND1* gene with the immunoglobulin heavy chain locus, driving constitutive cyclin D1 overexpression and uncontrolled cell cycle progression
Personalize your experience
Follow Mantle cell lymphoma and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.